Product Description
Ensartinib (X-396), is a potent, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma. Also, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Ensartinib (X-396), is a potent, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma. Also, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Biovision | B1946 | Ensartinib DataSheet
Alternate Name/Synonyms: (R)-6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide; X396
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1365267-27-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₅H₂₅Cl₂FN₆O₃
Molecular Weight: 547.41
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent anaplastic lymphoma kinase (ALK) inhibitor
MDL Number: N/A
PubChem CID: 56960447
SMILES: CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=CC(=NN=C2N)C(=O)NC3=CC=C(C=C3)C(=O)N4CCN(CC4)C
InChi: InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1
InChi Key: ONPGOSVDVDPBCY-CQSZACIVSA-N